colchicine – Medxy AI

Colchicine for Secondary Prevention After Stroke According to the Presence of Atherosclerosis: Clinical Evidence and Implications

By MedXY 08/21/2026

This review synthesizes evidence on colchicine's efficacy in secondary stroke prevention, emphasizing the impact of concomitant atherosclerosis on outcomes from the CONVINCE trial and meta-analyses.

Cardiology Neurology news

Evaluating Low-Dose Colchicine for Preventing Vascular Events After Acute Intracerebral Hemorrhage: Insights from a Placebo-Controlled Pilot Trial

By MedXY 08/09/2026

This pilot randomized trial demonstrates the feasibility of using low-dose colchicine after acute intracerebral hemorrhage to prevent vascular events, highlighting considerations for future larger studies regarding recruitment, adherence, and discontinuation rates.

Cardiology Hematology-Oncology news

Colchicine May Curb the Expansion of Pro-Inflammatory Clonal Hematopoiesis: Insights From the LoDoCo2 Substudy

By MedXY 01/17/2026

A substudy of the LoDoCo2 trial suggests that low-dose colchicine may attenuate the expansion of specific clonal hematopoiesis driver mutations, particularly TET2, offering a potential mechanism for reducing cardiovascular risk by slowing the proliferation of high-risk inflammatory clones.

Infectious Diseases Internal Medicine news

Colchicine for Long COVID: Randomized Trial Finds No Benefit in Functional Recovery or Inflammatory Resolution

By MedXY 01/01/2026

A multi-center randomized clinical trial published in JAMA Internal Medicine demonstrates that colchicine, despite its potent anti-inflammatory properties, fails to improve 6-minute walk test distances or inflammatory markers in patients suffering from Long COVID, highlighting the complexity of the condition's pathogenesis.

Cardiology Neurology news

Low-Dose Colchicine Reduces Myocardial Infarction and Stroke Risk in Cardiovascular Disease Patients

By MedXY 12/16/2025

A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.

Cardiology news

Low-Dose Colchicine in Acute Myocardial Infarction: Insights from an Updated Meta-Analysis

By MedXY 10/12/2025

An updated meta-analysis evaluates the effects of 0.5 mg colchicine on clinical outcomes after acute myocardial infarction, showing reduced hospital readmission but increased diarrhea risk without significant impact on major cardiovascular events.